T here is increasing evidence that the octapeptide angiotensin II (Ang II), the biologically active component of the renin-angiotensin system, is not exclusively formed in plasma but also in various tissues. Almost half a century ago, it was postulated that an angiotensin I (Ang I)-forming enzyme is present in extrarenal arterial walls and that this participates in the pathogenesis of essential hypertension. 1 In the meantime, Ang I-forming angiotensinogenases have been demonstrated in extrarenal vasculature of various animal species. 2 Furthermore, it has been found that extrarenal arterial wall Ang I-forming angiotensinogenases, biochemically different from renal renin, are stimulated in spontaneously hypertensive rats. 3 - 4 Recently, we noticed in the rat that those nonrenin Ang I-forming angiotensinogenases identified in extrarenal arteries are also contained in the kidney, although renal renin was scarcely demonstrable in extrarenal vasculature (authors' unpublished observations).
The intention of the present study was to identify Ang I-forming angiotensinogenases in human extrarenal vasculature, to establish whether these enzymes are also present in kidney, heart, and plasma, and to determine whether they are affected in essential hypertension.
Methods
Human vascular sections were obtained from individuals undergoing corrective surgery. Patients with essential hypertension were compared with normotensive patients; patients with secondary forms of hypertension were excluded. Routine biochemistry was normal in this population (including lipid values). In all hypertensive patients, antihypertensive therapy was discontinued for at least 1 week before surgery. Umbilical cord blood vessels derived from parturient women and cardiac tissues from explanted hearts that were not suitable for transplantation were used in this study. Plasma was collected from anephric patients and healthy individuals.
The tissues were cut into small pieces approximately 0.5 mm thick; they were homogenized in 0.9% saline (1 : 8) with a Potter-Elvehjem homogenizer (Braun, Melsungen, FRG) (six times at 30 seconds each) and subsequently with an ultrasonic disintegrator (MSE Ltd., Crawley, Sussex, England) (six times at 1 second each, 6 fim). The suspensions were centrifuged at 8,050 g for 1 minute, and the supernatants were used. All procedures were carried out below 4° C.
Ang I-forming angiotensinogenase activities were measured enzyme-kinetically by using the Ang I radioimmunoassay 3 and sheep or, in some cases, human angiotensinogen. Renin substrates were prepared as described previously. 5 Tissue extract (0.1 ml) was incubated at 37° C with 0.1 ml of 0.3 M phosphate buffer containing the angiotensinogen (approximately 800-1,200 ng/ml) and angiotensinase inhibitors. Final concentrations were (M) EDTA 3.3, 8-hydroxyquinoline sulfate 10.5, 2,3-dimercaptopropanol-1 4.9, and diisopropyl fluorophosphate 3.6. Plasma renin activity was likewise determined but without the addition of angiotensinogen. Angiotensin converting enzyme was assayed by the fluorimetric method of Piquilloud et al 6 with Z-Phe-His-Leu as substrate. Ang I-degrading enzyme activities were quantified as described recently. 4 Separations and biochemical characterizations of the enzymes were Statistical analysis and significance of results were calculated by standard methods. Student's t test was used for paired or unpaired samples, as appropriate, and for correlation coefficients.
Results
Some enzyme kinetic assays of tissue Ang Iforming angiotensinogenases are illustrated in Figure  1 coincidence of pH optima, arbitrary en2yme units were used for the ordinate. Figure 2 illustrates the results of fast protein liquid chromatography of kidney cortex Ang I-forming angiotensinogenases. Three different peaks were obtained, and the respective pH optima were measured as indicated. Because the enzyme assays were carried out under different conditions, the activities of the peaks cannot be compared. By means of the fast protein liquid chromatography technique, the following isoelectric points were determined for extrarenal arterial Ang I-forming angiotensinogenases: 6.46, 6.24, 5.92, 5.75 (renal renin, 5.4). The molecular weights of the extrarenal arterial enzymes were found to be between 20,800 and 24,900 (renal renin, 43,000). Figure 3 demonstrates the distribution of specific vascular and cardiac Ang I-forming angiotensinogenase activities. Heart tissues contained the highest enzyme levels, followed by carotid artery intima and other (whole) arteries. For veins, distinctly lower values were obtained than for the arteries. The values of umbilical cord blood vessels and serum are also plotted. The results for the umbilical cord vasculature are shown in more detail in Figure 4 , together with those of angiotensin converting enzyme and Ang I-degrading enzyme. Significant differences were obtained for the arterial and venous activities of all enzymes assayed. Arterial Ang I-forming angiotensinogenase and Ang I-degrading enzyme values exceeded those of the veins, but angiotensin converting enzyme behaved inversely. . No significant differences were obtained, although activities tended to decline in carotid artery intima of hypertensive patients. To test whether relations exist between both vascular enzymes or between them and plasma renin or other components of the renin-angiotensin system, the respective correlation coefficients r and probabilities p were evaluated. The results are as follows: arterial Ang I-forming angiotensinogenase (pH optimum 5.1) compared with arterial Ang I-forming angiotensinogenase (4.0): r=0.73, /?<0.001, n=35; arterial Ang I-forming angiotensinogenase (5.1) compared with plasma renin activity: r=0.8, p<0.05, n=6; arterial Ang I-forming angiotensinogenase (4.0) compared with plasma renin activity: r=0.97, p<0.001, n=6; carotid artery intima Ang I-forming angiotensinogenase (5.1) compared with carotid artery intima angiotensin converting enzyme: r=0.78, p<0.01, n = 10; carotid artery intima Ang I-forming angiotensinogenase (4.0) compared with carotid artery intima angiotensin converting enzyme: r=0.6,p<0.05, n = !0. Figure 6 illustrates the effects of pH on human plasma Ang I-forming angiotensinogenase activities. In plasma of healthy individuals (middle panel), two major equal pH optima were determined at 6.2 and 5.3, and a minor one was determined at 7.2. In plasma of bilaterally nephrectomized patients (left panel), pH optima were not found at 6 
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A I degrading enzyme p<0.001 n = 33 umbilical cord at 6.8 and 4.1 instead. To clarify which of the plasma enzymes derive from the kidney, the pH curve of the control subjects was subtracted from that of the anephric patients. The resulting differences are depicted in the right panel. For this calculation, the overlapping parts of the neighboring maxima had to be taken into consideration. Increasing enzyme levels are positively, and decreasing levels are negatively, plotted. The resultant activities for the pH optima at 4.1 and 5.3 are clearly augmented. On the other hand, the peak at 6.2 (pH optimum of renal renin) disappeared almost completely, and the enzyme values at 7.2 remained constant.
Discussion
The identification and quantification of Ang Iforming angiotensinogenases in extrarenal vasculature was a prerequisite for the present study. Renin antibodies were not used for measurement of Ang I-forming angiotensinogenase activities because it is unknown whether they react with the extrarenal vascular enzymes. Molecular biological techniques for the identification of renal renin were not used for the same reason. In addition, these analytical methods cannot differentiate between the multiple forms of renin or reninlike enzymes presumably present in human extrarenal vasculature, as has been demonstrated for the rat. 7 Ang I-forming angiotensinogenase activities were thus assayed by enzyme-kinetically measuring the initial Ang I formation rate with purified natural angiotensinogen. Linearity of the kinetics shown in Figure 1 indicates that the analytical procedure was reliable. Human plasma renin consumes sheep angiotensinogen faster than the homologous substrate. nal arterial Ang I-forming angiotensinogenases to renal renin is supported by the observation that pepstatin (4xlO~5 M) quantitatively inhibits the vascular enzymes. However, the isoelectric points and the molecular weights of the extrarenal arterial enzymes are significantly different from the respective values of renal renin. Furthermore, the apparent K m of the vascular enzyme (pH optimum 5.1) distinctly exceeds that of renal renin (authors' preliminary observations). Those pH optima identified in rat and human extrarenal vasculature were also detected in renal and cardiac tissues; this finding suggests that the Ang I-forming angiotensinogenases of these organs are also contained in the vasculature (authors' unpublished observations). In human extrarenal vasculature, renal renin was present at relatively low activities or not at all. This has also been shown for the rat and indicates that the nonrenin Ang I-forming angiotensinogenases present in vascular tissues do not derive from the circulating blood.
The main aim of this study was to examine the theory of Jimdnez Dias et al, 1 which postulates the existence of renin or reninlike enzymes in human extrarenal arterial walls and their participation in pathogenesis of essential hypertension. The feasibility of this investigation mainly depended on the availability of suitable vascular samples. Because blood vessels from different regions had to be used initially, the distributions of Ang I-forming angiotensinogenases in different vascular tissues were measured. Consistent with results obtained earlier for the rat, highest Ang I-forming angiotensinogenase levels were found in the heart. 9 This observation can be explained by the fact that specific Ang I-forming angiotensinogenase activities increase with decreasing vascular diameters and that numerous small blood vessels are present in cardiac tissue. 10 The values obtained for (whole) arteries were slightly lower than those for carotid artery intima; this finding suggests luminal localization of the enzymes. The venous activities derive exclusively from varicose blood vessels and indicate that vascular Ang Iforming angiotensinogenases are suppressed in these pathological tissues. Likewise, the activities of umbilical cord vasculature are significantly lower than those of other blood vessels. Ang I-forming angiotensinogenase (pH optimum 5.4), angiotensin converting enzyme, and Ang I-degrading enzyme levels were determined simultaneously. Obviously, Ang II concentration is low in these arteries, when compared with others, because Ang I and Ang II formations are inhibited, while Ang I degradation is facilitated. The results suggest that in these blood vessels the vascular renin-angiotensin system scarcely affects fetal blood supply.
Although the existence of an extrarenal arterial Ang I-forming enzyme and its participation in essential hypertension has repeatedly been postulated, this hypothesis has not yet been confirmed in humans, The Ang I-forming angiotensinogenases are probably concentrated in the luminal parts of the arteries. However, it is also possible that the enzymes mediate special physiological functions in the carotid artery and thus are present there in higher concentrations. In essential hypertension, extrarenal arterial Ang I-forming angiotensinogenases are clearly not stimulated as previously postulated although there is a slight indication of greater scatter in the hypertensive patients than in the control subjects. Since in this disease plasma renin activities may be high, normal, or low, we wanted to establish whether the vascular enzymes behave similarly. The correlation coefficients and probabilities for the vascular Ang Iforming angiotensinogenases (pH optimum 5.1 and 4.0) and plasma renin were thus evaluated. The data obtained suggest the existence of subgroups of essential hypertensive patients with high, normal, and low extrarenal Ang I-forming angiotensinogenase activities and common controlling mechanisms for vascular Ang I-forming angiotensinogenases and plasma renin. Because extrarenal arterial Ang I-forming angiotensinogenases are generally stimulated in spontaneously hypertensive rats, these animals can only be assumed to be a model for that subgroup of essential hypertension with elevated vascular Ang I-forming angiotensinogenase activities. Finally, we wanted to establish whether the Ang I-forming angiotensinogenases in extrarenal vasculature are demonstrable in plasma. For this purpose, the effect of pH on plasma Ang I-forming angiotensinogenase activities was studied. Two major and two minor pH peaks were found. Clearly, bilateral nephrectomy affected the plasma enzymes. A significant diminution was observed at pH 6.2, which indicated an enzyme derived from the kidney. However, the heights of two other pH optima (at 4.0 and 5.3) increased distinctly. Ang I-forming angiotensinogenases with the same pH optima are contained in extrarenal arterial walls and are also present in the kidney. However, in renal extract the vascular pH optimum is superimposed by that of the main form of kidney renin. Initial investigations performed by fast protein liquid chromatography confirm this assumption ( Figure 2 ). Although bilateral nephrectomy should reduce the activities of those vascular Ang I-forming angiotensinogenases released by the kidney, such a diminution was not observed. Therefore, we assume that removal of the kidneys causes an effective stimulation of these enzymes, possibly due to the drastic reduction of plasma renin activity.
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The experimental results obtained indicate the existence of an intrinsic human vascular reninangiotensin system also contained in the kidney and heart and interrelated with the plasma system. The postulate of its general stimulation in essential hypertension could not be confirmed.
